Cocrystals, also written co-crystals, are neutral crystalline solids containing API and coformer. Screening and coformer selection can identify forms that tune aqueous solubility, dissolution, hygroscopicity, highly disordered desolvated-solvate behavior, lipophilicity, bioavailability, stability, melting point, API purity, developability, and intellectual property position.
Cocrystals can create crystalline forms of APIs previously known only as amorphous forms, improve melting points, improve chemical purity, reduce light-related degradation, reduce hydrate risk in formulation, and improve solubility or bioavailability.
A cocrystal screen is usually considered when a suitable salt cannot be found, the molecule is non-ionizable, or a crystalline property-improvement and IP strategy is needed.
The development value of a cocrystal depends on a measurable property gain and a credible path to control. If the cocrystal improves solubility but converts to the parent API during dissolution or storage, the program needs residual-solid analysis and formulation mitigation before the form is treated as a lead.
Triclinic uses an expanded coformer list and a phase-diagram-guided approach rather than relying only on generic combinatorial screening. Establishing phase relationships can support a more intelligent approach to solid-form screening and can help predict undiscovered solid forms or instability.
Cocrystal hits are characterized by melting behavior, stoichiometric domains, XRPD and/or Raman fingerprints, and downstream performance. Reaction conditions include stoichiometric wet milling and solvent-drop grinding, non-stoichiometric slurry conversion, thermal methods, mechanical processing, sonication, Kofler/binary melt methods, and individual vial screening where appropriate.
Phase relationships also reduce false confidence. A new thermal event or pattern shift can be a useful clue, but it should be tied to stoichiometry, stability domain, and reproducible preparation before it is used to support form selection or IP strategy.
Cocrystal formulation is often a supersaturation problem. The cocrystal can set the spring by generating a higher API concentration, but formulation must open the parachute by delaying crystallization long enough for absorption.
Higher cocrystal loading does not automatically improve exposure. Once supersaturation is too high, API crystallization can accelerate and reduce the benefit. Therefore cocrystal selection should include dissolution, crystallization-inhibition, and formulation stress experiments.
A cocrystal program should not stop at a new XRPD pattern. The decision is whether the new multicomponent crystal improves a property that matters and remains controllable during crystallization, formulation, storage, dissolution, release testing, and lifecycle changes.
Triclinic uses coformer selection, reaction-condition diversity, phase-diagram logic, and orthogonal characterization to separate true cocrystals from salts, eutectics, physical mixtures, solvates, hydrates, and metastable artifacts.
Cocrystals are strategic when the API is non-ionizable, salt formation fails, or the program needs to tune solubility, hygroscopicity, stability, purification, chiral resolution, mechanical properties, bioavailability, or IP position.
A cocrystal screen should begin with API evaluation and coformer selection, then move into experimental design. Useful inputs can include hydrogen-bond donor/acceptor complementarity, symmetry, salt-forming potential, molecular electrostatic potential, coformer safety, size and flexibility, solubility, and chemical stability.
| Decision signal | What to test | Actionable output |
|---|---|---|
| Non-ionizable API | Provides a solid-form option when proton-transfer salt formation is unavailable. | Select coformers rationally and confirm the resulting solid state. |
| Salt failure | Can improve properties without relying on a problematic counterion. | Compare cocrystal behavior against salt, free form, and formulation alternatives. |
| Hygroscopicity or stability issue | A coformer may reduce water uptake or stabilize a troublesome form. | Stress candidate forms under humidity, solvent, and formulation-relevant conditions. |
| Purification or chiral selectivity | Crystal packing can reject impurities or discriminate between components. | Document solid-form identity and property relevance. |
A Purdue Pharma cocrystal example illustrates how a cocrystal can show improved dissolution and in vivo exposure relative to the parent API form when formulation and physical stability are aligned.
Determine whether an API can exist in multiple crystalline forms and whether form differences change solubility, dissolution, stability, manufacturing, drug-product performance, or IP.
View serviceScreen ionizable APIs for counterions that improve crystallinity, solubility, dissolution, stability, manufacturability, or developability while controlling disproportionation risk.
View serviceCharacterize non-crystalline materials, local order, recrystallization risk, spray drying feasibility, polymer selection, drug loading, and solid-dispersion stability.
View serviceBuild reproducible crystallization processes that control the chosen solid form, particle attributes, purity, and scale-up behavior.
View serviceResolve form conversion, failed crystallizations, process sensitivity, stability drift, unexplained PK/dissolution changes, and batch-to-batch material differences.
View servicePharmaceutical cocrystals and salts are both multicomponent crystalline materials, but they differ principally in the extent of proton transfer between the API and the second component. A salt contains ionized API and counterion species, whereas a cocrystal is generally composed of molecular components associated predominantly through nonionic interactions. The distinction may be clear in strongly acidic or basic systems but can become difficult in borderline cases, requiring structural, spectroscopic, and compositional evidence.
A cocrystal screen should be considered when the selected free form or salt does not adequately meet the target product profile, or when an alternative solid form could improve solubility, dissolution, stability, mechanical properties, hygroscopicity, or manufacturability. Cocrystals are particularly relevant for neutral or weakly ionizable APIs that are poor candidates for salt formation, but they may also be useful for ionizable APIs when available salts are unstable, hygroscopic, poorly soluble, or difficult to process.
Yes, cocrystals can improve bioavailability when they increase dissolution, generate useful supersaturation, improve formulation performance, or alter other absorption-limiting properties. The effect is not automatic. A cocrystal may dissociate or convert to a less soluble API phase before absorption, and improved in vitro solubility does not necessarily produce greater in vivo exposure. Bioavailability improvement must be demonstrated using phase-aware dissolution, precipitation, permeability, pharmacokinetic, and formulation studies appropriate to the compound.
Cocrystals dissociate during dissolution because the API and coformer are held together by noncovalent interactions rather than covalent bonds. Once the crystal contacts a solvent, the components may dissolve at different rates, and the solution may favor separate dissolved species or precipitation of a more stable API phase. Dissociation is especially likely when the coformer is much more soluble than the API, when solution pH strongly ionizes one component, or when the cocrystal generates API supersaturation that is not kinetically maintained.
Cocrystal formers are selected by combining crystal-engineering principles with pharmaceutical-development requirements. Scientists evaluate complementary hydrogen-bonding functionality, molecular shape, pKa, solubility, chemical compatibility, coformer safety, dose burden, route of administration, and the property the cocrystal is intended to improve. Computational and database methods can prioritize candidates, but experimental screening remains necessary because cocrystal formation and developability cannot be predicted reliably from molecular structure alone.
Cocrystal formation is confirmed most reliably through orthogonal characterization. XRPD demonstrates formation of a new crystalline phase, while thermal analysis, spectroscopy, compositional testing, and structural methods help establish stoichiometry, solvent or water content, molecular interactions, and whether the material is a neutral cocrystal, salt, solvate, hydrate, or physical mixture. No single technique answers every relevant question.
Regulatory expectations focus on correct classification, adequate characterization, reproducible manufacture, coformer acceptability, stability, and control of attributes that affect product quality or performance. FDA’s final February 2018 guidance addresses the classification of pharmaceutical cocrystals in NDAs and ANDAs and the supporting information applicants should provide. A cocrystal should not be treated as a simple physical mixture merely because the API remains covalently unchanged.
Common pitfalls include treating every new XRPD pattern as a cocrystal, selecting coformers without considering safety or dose burden, screening too narrowly, optimizing only solubility, failing to investigate dissociation and precipitation, overlooking polymorphs and hydrates, and advancing a material that cannot be manufactured reproducibly. A successful cocrystal must provide a durable product advantage and remain controllable throughout processing, storage, dissolution, and commercial manufacture.
Send the material history, current data package, process conditions, development objective, and timeline. Triclinic will route the request to the right solid-form scientist.
